dabigatran has been researched along with Adverse Drug Event in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (73.08) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Horwitz, H; Jimenez-Solem, E; Nyeland, ME; Schelde, AB; von Osmanski, BI | 1 |
| Edwards, JK; Lund, JL; Poole, C; Simpson, RJ; Stürmer, T; Webster-Clark, M | 1 |
| Bernardini, F; Marchetti, G; Romoli, M; Urbinati, S | 1 |
| Dvorackova, S; Jirsova, E; Kolar, J; Kubena, AA; Mala-Ladova, K; Maly, J; Steurbaut, S; Zimcikova, E | 1 |
| Ishizawa, K; Mitsuboshi, S; Niimura, T; Zamami, Y | 1 |
| Luna, JD; Manzano-Gamero, V; Pardo-Cabello, AJ | 1 |
| Ageno, W; Barco, S; Binder, H; Brenner, B; Duerschmied, D; Empen, K; Faggiano, P; Ficker, JH; Galiè, N; Ghuysen, A; Held, M; Heydenreich, N; Huisman, MV; Jiménez, D; Klok, FA; Konstantinides, SV; Kozak, M; Lang, IM; Lankeit, M; Meyer, G; Münzel, T; Petris, A; Pruszczyk, P; Quitzau, K; Schellong, S; Schmidt, KH; Stefanovic, BS; Verschuren, F; Wolf-Puetz, A | 1 |
| Ding, YF; Gu, ZC; Li, J; Lin, HW; Liu, D; Liu, XY; Pu, J; Wei, AH; Zhang, C | 1 |
| Karakas-Torgut, A; Mo, Y; Pham, AQ | 1 |
| Bakkehøi, G; Eek, AK; Stenberg-Nilsen, H; Strøm, BO | 1 |
| Bertlich, M; Bootz, F; Eichhorn, KW; Freytag, S; Gräff, I; Horlbeck, F; Jakob, M; Schafigh, D; Send, T | 1 |
| Aisenberg, J; Elsaesser, A; Glund, S; Huisman, MV; Klok, FA; Lopes, RD; Pollack, CV; Reilly, P; Van der Wall, SJ; van Ryn, J | 1 |
| Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A | 1 |
| Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E | 1 |
| Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB | 1 |
| Asirvatham, SJ; Noheria, A | 1 |
| Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S | 1 |
| Gagne, JJ; Glynn, RJ; Schneeweiss, S; Wangge, G | 1 |
| De Smet, M; Gansser, D; Glund, S; Haazen, W; Kreuzer, J; Lang, B; Moschetti, V; Norris, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J | 1 |
| Dickfeld, T; Goldner, R; Schleichert, R | 1 |
| Dyrkorn, R; Lundgaard, H; Molden, E; Spigset, O; Stokes, CL | 1 |
| Baldelli, S; Cattaneo, D; Cerea, M; Clementi, E; Pignatelli, P; Violi, F | 1 |
| Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F | 1 |
| Kowey, PR; Naccarelli, GV | 1 |
| Barsness, GW; Caprini, J; Clemens, A; Eriksson, BI; Feuring, M; Hantel, S; Schnee, J; Smith, JJ | 1 |
| Livio, F | 1 |
3 review(s) available for dabigatran and Adverse Drug Event
| Article | Year |
|---|---|
Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies.
Topics: Anticoagulants; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial Infarction; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2018 |
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Observational Studies as Topic; Postoperative Complications; Premedication; Risk Factors; Thromboembolism; Treatment Outcome | 2013 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydrochloride; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Fibrinolytic Agents; Fumarates; Hemorrhage; Humans; Pharmacovigilance; Propylamines | 2013 |
4 trial(s) available for dabigatran and Adverse Drug Event
| Article | Year |
|---|---|
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Topics: Acute Disease; Anticoagulants; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Hemorrhage; Heparin; Humans; Male; Prospective Studies; Pulmonary Embolism; Recurrence; Reference Standards; Research Design; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Postoperative Complications; Premedication; Risk Factors; Thromboembolism; Treatment Outcome; United States; Warfarin | 2013 |
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Cross-Over Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Humans; Male; Middle Aged; Retreatment | 2016 |
Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Benzimidazoles; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Incidence; Internationality; Male; Middle Aged; Orthopedics; Postoperative Complications; Pyridines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Thrombosis; Treatment Outcome | 2012 |
19 other study(ies) available for dabigatran and Adverse Drug Event
| Article | Year |
|---|---|
Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug-Related Side Effects and Adverse Reactions; Humans; Intracranial Hemorrhages; Pyridones; Rivaroxaban; Warfarin | 2022 |
Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Hemorrhage; Health Services for the Aged; Humans; Male; Medicare; Risk Factors; Stroke; United States; Warfarin | 2020 |
Switching across direct oral anticoagulants: a real-life-setting pilot prospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Dabigatran; Drug Monitoring; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Female; Heart Disease Risk Factors; Humans; Italy; Long Term Adverse Effects; Male; Medication Therapy Management; Risk Adjustment; Rivaroxaban | 2021 |
Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Czech Republic; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Retrospective Studies; Stroke; Warfarin | 2021 |
Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2021 |
Comparative study of adverse drug reactions among direct-acting oral anticoagulants and vitamin K antagonists using the EudraVigilance database.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Vitamin K; Young Adult | 2021 |
Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dabigatran; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Hospitals, Urban; Humans; Male; Middle Aged; Pyridones; Retrospective Studies; Rivaroxaban | 2020 |
Anticoagulant-associated adverse drug reactions in 2013-15.
Topics: Age Distribution; Anticoagulants; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Distribution; Time Factors; Warfarin | 2018 |
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Epistaxis; Female; Follow-Up Studies; Germany; Hospitalization; Humans; Length of Stay; Male; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Risk Assessment; United States; Venous Thromboembolism; Vitamin K | 2019 |
Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Japan; Length of Stay; Male; Middle Aged; Premedication; Risk Factors; Thromboembolism; Treatment Outcome | 2013 |
Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Premedication; Risk Factors; Thromboembolism; Treatment Outcome | 2013 |
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor VIIa; Hemorrhage; Humans | 2014 |
Developing alerting thresholds for prospective drug safety monitoring.
Topics: Anticoagulants; Benchmarking; Clinical Trials as Topic; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Pharmacoepidemiology; Product Surveillance, Postmarketing; Risk; Warfarin | 2016 |
Palmoplantar pustular eruption due to dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Biopsy; Dabigatran; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Eczema, Dyshidrotic; Female; Humans; Psoriasis; Skin; Skin Diseases, Eczematous; Stroke | 2016 |
[Safer treatment with serum concentration monitoring of the new anticoagulants?].
Topics: Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Pyrazoles; Pyridones; Reference Standards; Risk Factors; Rivaroxaban; Vitamin K | 2016 |
Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy.
Topics: Anticoagulants; Antithrombins; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans | 2016 |
Italian intersociety consensus on DOAC use in internal medicine.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism | 2017 |
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Assessment; Stroke; Thrombin; United States; United States Food and Drug Administration | 2012 |